I listened to a discussion recently on the discount rates used to value pharmaceutical and biotechnology products. One of the speakers suggested that the same asset should have a higher value (via a lower discount rate) if it were being developed by Pfizer Inc.* for example, than by a smaller biotech company. This is logical because an asset in an area where Pfizer has therapeutic and commercial expertise should have better quality resources behind it and Pfizer’s previous experience in that therapeutic area should also increase the chances of success. In addition, a new product enlarging an existing therapeutic portfolio at Pfizer has the advantage of not building out a de novo commercial infrastructure at a smaller biotech company. However, I wondered if these assumptions were always true and if enough track-record risk is captured in company valuations.
Stock Watch: Risk And The Pharmaceutical Discount Rate
Track Records May Not Be Reflected Even In Risk-Adjusted Valuations
In contrast to the SEC’s view that public companies’ regulatory filings give investors all the information needed to make an investment decision, the discount rate used to value a company may not reflect all its risks.
More from Stock Watch
More from Business
Private Company Edition: The latest group of drug developers to announce venture capital financings is remarkable for its geographic diversity, from Character Biosciences’ $93m series B round in the US to Augustine’s $85m series B in Belgium to a $29.2m series C for Aculys in Japan.
The head of the Spanish medical dermatology specialist told Scrip that maintaining the status quo will only result in the continent’s life sciences sector slipping further behind the US and China.
Stakeholders are pleading for newly confirmed FDA Commissioner Martin Makary to stand up for the agency's high scientific standards and staff as he begins his term.